LTS and AVAYL: Transformative collaboration in life sciences through 5-HT

How AI creates real value: transformative collaboration between LTS and AVAYL - the partnership between LTS and AVAYL impressively demonstrates how artificial intelligence can be used effectively in life science organizations.

The collaboration came about through active networking by 5-HT and was presented at the 5-HT Innovators Club by LTS and AVAYL in September 2024.

Dr. Patrick Mohr, Corporate Vice President R&D at LTS, and Dr. Miena Amiri, CEO AVAYL, at the 5-HT Innovators Club in September 2024 Heidelberg

AVAYL - AI innovation meets pharmaceutical expertise

AVAYL is a global partner for leading life science organizations and supports medical information processes with AI-supported software. Founded by a medical doctor from the pharmaceutical industry and a physicist from the semiconductor industry, AVAYL is headquartered in Berlin.

In the life sciences industry, where products are strictly regulated and medical evidence plays a central role, millions of scientific data need to be analyzed and translated into medical information and insights every year. This is crucial in order to remain competitive and meet regulatory requirements. Artificial intelligence offers enormous potential here, but the highly regulated and scientific environment requires specialized solutions.

Dr. Amiri explains AVAYL's vision: “Our vision is a world in which medical information is available as quickly as the latest research results. We support our customers in accessing relevant data more quickly and thus accelerating ideal care."

AVAYL works with leading companies and industry associations to provide solutions that enable users to understand and compare clinical evidence faster and make the right decisions.

Dr. Miena Amiri (CEO), Alexander Götz (CTO), AVAYL GmbH

LTS - Pioneering work in the pharmaceutical industry

LTS Lohmann Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, is demonstrating through its partnership with AI startup AVAYL how artificial intelligence can be used in a targeted manner to optimize various processes in the pharmaceutical sector and make them more efficient. The collaboration began in fall 2023, when LTS was looking for an innovative partner that could master state-of-the-art AI technology in this challenging environment. The aim was to speed up the company's own work processes and develop cross-functional solutions.

Several initiatives were launched as part of the project. With the help of MedPro, AVAYL's AI-supported platform, medical-scientific and clinical data on therapeutic fields and molecules were systematically analyzed and evaluated with the aim of obtaining more efficient and effective results.

The collaboration - effectiveness through AI

In order to select the right partner for their technologies, LTS contacted AVAYL via 5-HT. AVAYL's AI-powered MedPro platform provided the solution LTS needed to accelerate systematic literature analysis, create scientific content and enable faster drug evaluation. Dr. Patrick Mohr, Corporate Vice President and Head of Pharmaceutical Development R&D at LTS, explains: “The challenges we were facing required a solution that was not only accurate and reliable, but also flexible enough to address our specific needs. With AVAYL, we found exactly that.”

The solution - Customized AI for the pharmaceutical industry

MedPro provides support with various critical tasks, such as screening and summarizing scientific studies, answering specific questions about extensive literature and creating material that can be used, for example, as a basis for internal decision-making or for communication with partners and customers.

The implementation was carried out in close cooperation between the two companies. “We chose an iterative approach in which we were in constant communication with LTS in order to tailor the solution to their needs,” explains Dr. Amiri. “At the same time, we validated the solution with other customers and industry associations to ensure scalability and compliance with regulatory and quality standards.”

“This approach proved beneficial in meeting the specific requirements of the pharmaceutical industry. MedPro works exclusively with verified scientific data sets in combination with the company's own data.

It was important to us that the experts always retain control over the workflow.”

Successes and future prospects

As a result of the collaboration, LTS has been able to record its first significant time savings and increased effectiveness. Dr. Mohr reports: “We have been able to significantly reduce the amount of manual research and analysis required for medical issues. This leads to faster decision-making and will enable us to place innovative products even better in the long term.”

“The work is not done yet. We are convinced that these are initial short-term successes, but that we can continue to leverage further value for the benefit of our customers,” explains Dr. Amiri. “Ultimately, it's about enabling patients to benefit more quickly from the latest scientific information and innovations from our partners.”

A look into the future - partnership with potential

The collaboration between LTS and AVAYL shows how successful co-development between established companies and new providers can be implemented. At LTS, the R&D, marketing and market intelligence teams are already benefiting from the AVAYL solution.

The constructive collaboration and focus on positive impact has been particularly positive. Dr. Amiri comments: “LTS is a fantastic collaboration partner. Our joint mission is to combine our expertise and use of the latest technology to provide better services to our customers. At the same time, it was important to iterate and prioritize to ensure that we achieve the common goal.”

Dr. Mohr is optimistic about the future: “We are convinced that the partnership will have a long-term impact on LTS and will be used profitably. By working with AVAYL, we are setting new standards for the future.”

LTS Lohmann Therapie-Systeme AG, based in Andernach